• The technology described in this briefing is the QAngio XA 3D/QFR imaging software. It is used to assess fractional flow reserve (FFR) non-invasively.

  • The innovative aspects of the technology are its ability to use invasive coronary angiography (ICA) to measure FFR non-invasively, quickly, on site and without the need for adenosine.

  • The intended place in therapy would be in people with chest pain of recent onset who are referred for investigative ICA, and in people having a percutaneous coronary intervention (PCI) in which the technology could prevent the need for a pressure wire.

  • The main points from the evidence summarised in this briefing are from 4 multicentre prospective studies including 568 adults referred for ICA. They show that QAngio XA 3D/QFR shows high correlation with the results from pressure-wire FFR.

  • Key uncertainties around the evidence or technology are that the evidence is limited but evolving, and it is uncertain how the technology would translate into UK clinical practice given current recommendations in NICE's guideline on chest pain.

  • The cost of QAngio XA 3D/QFR is £150 to £250 per analysis (excluding VAT). The resource impact would be cost saving if the technology avoided the need for invasive investigation and measurement of fractional flow.